In the field of CRC, Du and collaborators [46] revealed that PrPC expression defines a subpopulation of CD44-positive CSCs (PrPC+CD44+) with high liver metastatic capability in orthotopic xenograft models, an effect significantly inhibited by administration of PrPC monoclonal antibodies. This evidence concerns the gene CD44 and colorectal carcinoma.